|
Jul 2
|
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
|
|
Jun 30
|
Changes to the Roche Enlarged Corporate Executive Committee
|
|
Jun 27
|
Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US
|
|
Jun 26
|
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
|
|
Jun 26
|
Innovation in Focus: Highlights from the Two-Day London Biotechnology Show 2025
|
|
Apr 7
|
Sarepta and Roche aim to resume paused Elevidys trials following patient death
|
|
Apr 4
|
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
|
|
Apr 4
|
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
|
|
Apr 4
|
AD/PD 2025: Roche’s Brainshuttle technology promises next generation of amyloid beta mAbs
|
|
Apr 3
|
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
|
|
Apr 3
|
AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s
|
|
Apr 3
|
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
|
|
Apr 3
|
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
|
|
Apr 3
|
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
|
|
Apr 3
|
IoT can help to reduce the burden of clinical trials on patients
|
|
Apr 3
|
AD/PD 2025: Roche highlights time-to-event for assessing prasinezumab in early PD
|
|
Apr 3
|
Roche’s high-dose Ocrevus fails primary endpoint in MS trial
|
|
Apr 2
|
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
|
|
Apr 2
|
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
|
|
Apr 2
|
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
|